Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II)

Trial Profile

Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Buparlisib (Primary)
  • Indications Glioblastoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors SCRI Development Innovations
  • Most Recent Events

    • 16 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
    • 28 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
    • 28 Jul 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top